Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease that affects motor neurons, leading to muscle weakness, paralysis, and eventually respiratory failure. Symptoms often begin with muscle twitching and weakness in the limbs. ALS affects approximately 20,000 to 30,000 people in the United States, with a global prevalence of 2-3 per 100,000 people. The ALS drug market is currently valued at around $1.5 billion, with projected growth. The FDA-approved drug riluzole and edaravone are currently used to slow disease progression, but there is no cure. Developing new drugs offers significant potential, as ALS remains a challenging and fatal disease with limited effective treatment options.
Zebrafish Model: Using a novel method in 6 dpf larvae to identify potential drugs to cure ALS